FDA Grants AP Status for Valproic Acid ANDA090517 by Quagen
The FDA has granted Abbreviated Approval (AP) status for Quagen's ANDA090517 for Valproic Acid.
Asset / Drug
Drug and asset intelligence for Quagen with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.